PBS Update: Hep C and two new cancer drugs listed
One treatment has just been listed and two more will take effect from 1 May
A new treatment has been listed on the PBS for people with hepatitis C who have failed on other therapies.
Vosevi (Gilead Sciences) is a fixed dose combination of sofosbuvir (400mg), velpatasvir (100mg) and voxilaprevir (100mg).
It is indicated for patients with chronic hepatitis C infection without cirrhosis for all genotypes (1-6) who have failed treatment with a regimen containing a non-structural protein 5A (NS5A) inhibitor.
It is estimated that about 3.5% of patients with hepatitis C fall into this category.
